P019 - CLINICAL EFFICACY OF ANTI-TNFA ANTIBODY TREATMENT IN PATIENTS WITH DEFINITE OR SUSPECTED INTESTINAL BEHCET DISEASE
(Room Poster Hall)
19 Jan 18
5:30 PM
-
7:00 PM
Tracks:
Clinical and Research Challenges
Background: Although anti-TNFα antibody treatment has been used for definite or suspected intestinal Behcet disease (BD), the efficacy of the treatment remains elusive. Methods: We performed a retrospective analysis of 10 patients with definite or suspected intestinal BD who were treated by anti-TNFα antibody treatment from July 2006 to August 2016. We evaluated the clinical response and remission rates at weeks 8, 26, and 52. We also investigated clinical predictors associated with clinical remission at week 8 and with secondary failure. The clinical activity was assessed using DAIBD (Disease Activity Index for Intestinal Behcet's Disease). Among patients who could achieve clinical response during observation period, secondary failure of the treatment was assessed. Results: The proportions of clinical response at weeks 8, 26, and 52 were 100%, 80% and 70%, respectively. Clinical remission rates at the respective evaluation period were 70%, 80%, and 70%. The DAIBD at baseline among 3 patients who failed to achieve clinical remission at week 8 was significantly higher than the values among the patients who could achieve clinical remission at week 8 (P = 0.01). Secondary failure was determined in 1 patient (10%) at week 26, and in 3 patients (30%) at week 52. All 3 patients who experienced secondary failure at week 52 had failed to achieve clinical remission at week 8. The remaining 7 patients who sustained clinical remission had achieved clinical remission at week 8. There was no side effect associated with anti-TNFα antibody during the average observation period of 5.5 years. Conclusion: Anti-TNFα antibody treatment is effective and well tolerated for definite and suspected BD. The high DAIBD value at baseline is suggested to be predictive of poor short-term and long-term clinical efficacy of the treatment in intestinal BD.